RESEARCH ARTICLE

Cost-effectiveness of breast cancer screening using mammography in Vietnamese women

Chi Phuong Nguyen1*, Eddy M. M. Adang2*

1 Department of Pharmaceutical Administration and Economics, Hanoi University of Pharmacy, Hanoi, Vietnam, 2 Department of Health Evidence, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

These authors contributed equally to this work.

Current address: Department of Health Evidence, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands

* chinguyen@hup.edu.vn

Abstract

Background

The incidence rate of breast cancer is increasing and has become the most common cancer in Vietnamese women while the survival rate is lower than that of developed countries. Early detection to improve breast cancer survival as well as reducing risk factors remains the cornerstone of breast cancer control according to the World Health Organization (WHO). This study aims to evaluate the costs and outcomes of introducing a mammography screening program for Vietnamese women aged 45–64 years, compared to the current situation of no screening.

Methods

Decision analytical modeling using Markov chain analysis was used to estimate costs and health outcomes over a lifetime horizon. Model inputs were derived from published literature and the results were reported as incremental cost-effectiveness ratios (ICERs) and/or incremental net monetary benefits (INMBs). One-way sensitivity analyses and probabilistic sensitivity analyses were performed to assess parameter uncertainty.

Results

The ICER per life year gained of the first round of mammography screening was US $3647.06 and US$4405.44 for women aged 50–54 years and 55–59 years, respectively. In probabilistic sensitivity analyses, mammography screening in the 50–54 age group and the 55–59 age group were cost-effective in 100% of cases at a threshold of three times the Vietnamese Gross Domestic Product (GDP) i.e., US$6332.70. However, less than 50% of the cases in the 60–64 age group and 0% of the cases in the 45–49 age group were cost effective at the WHO threshold. The ICERs were sensitive to the discount rate, mammography sensitivity, and transition probability from remission to distant recurrence in stage II for all age groups.
Conclusion

From the healthcare payer viewpoint, offering the first round of mammography screening to Vietnamese women aged 50–59 years should be considered, with the given threshold of three times the Vietnamese GDP per capita.

Introduction

Globally, breast cancer is the most prevalent cancer in women. In terms of mortality, breast cancer becomes the leading cause of cancer related death in women in developing countries and the second leading cause in developed countries [1–3]. Approximately 1.67 million new breast cancer cases were diagnosed (25% of all cancers) and 522,000 deaths from breast cancer occurred in 2012 all over the world [4]. Although breast cancer is thought to be a common female disease in high-income countries, nearly 50% of breast cancer cases and 58% of deaths due to breast cancer occur in low- and middle-income countries where the majority of women were diagnosed at the late stages [5]. Breast cancer is also the most common cancer among women in Vietnam. The incidence rate rose from 13.8 per 100,000 Vietnamese women (in 2000) to 28.1 per 100,000 Vietnamese women (in 2010). According to Duc NB, 12,533 women with breast cancer were diagnosed in 2010 [6]. Potentially explanatory factors for the rising rate of breast cancer in Vietnamese women were: the fall in fertility rate, the increase in overweight women, and the improved healthcare system (i.e., the increased availability of diagnostic tests) [7]. The peak age group of breast cancer was 50–54 years in Vietnamese women. Breast cancer is the third leading cause of death from cancer; only liver cancer and lung cancer account for more cancer deaths in Vietnamese women [8].

Early detection can improve breast cancer outcomes and the survival of breast cancer patients. The highest proportion of breast cancer patients in low and middle-income countries, including Vietnam, are diagnosed at the late stages which makes the treatment more difficult and costly [7]. Therefore, breast cancer screening in the general population could potentially reduce both the health burden and the economic burden of breast cancer. Although there are currently some breast cancer screening approaches, only mammography screening has been proven to reduce breast cancer mortality by early detection in population-based programs [2].

National mammography screening programs have been widely implemented including in Europe, North America, and Australia and the cost-effectiveness of these schemes has been published [9–12]. An estimated cost per life year gained of US$27,000 was found in the US [13] and US$19,919 in Australia [14]. In Asian countries, the cost per life year gained had a large range from US$19,257 (India) [15] and US$29,964 (South Korea) [16] up to US$64,400 (China) [17]. However, the guidelines of optimal screening policies (start age, end age, and interval screening) differ between countries. The American Cancer Society recommends that annual mammography screening for women begins at age 45 [18]. The Department of Health of the Australian Government recommends women aged between 50 and 74 years for biennial mammography screening. Factors such as age, breast tissue density, and screening interval, affect the sensitivity and specificity of mammography screening. Some Asian countries, such as South Korea, Japan, and Singapore, have initiated population-based screening programs. In South Korea, women are being screened with mammography every two years, starting at age 40 [19]. The Ministry of Health of Singapore recommends that biennial mammography screening should be implemented for women between 50–69 years [20]. According to Chisato
Hamashima et al., Japanese women between 40–74 years of age should be screened by mammography without clinical breast examination for population-based screening [21].

National mammography screening is presently not performed in Vietnam; there is only private screening (patients pay the screening fees) which hampers nationwide screening due to the financial barrier. The rate of uptake in private screening and information on the epidemiology of screened women are not available in Vietnam. It is not possible to perform the national mammography screening program for all Vietnamese women since the age-adjusted incidence rate is lower than that in other countries and the budget of the healthcare system is very limited. Therefore, the aim of this study is to estimate: (a) the cost-effectiveness of mammography screening among Vietnamese women; (b) the appropriate age category for the first round of mammography screening among Vietnamese women.

**Methods**

**Model structure and assumptions**

The screening strategy under evaluation is that women over 45 years of age are being screened by mammography. Four age groups were considered: 45–49, 50–54, 55–59, and 60–64 years. It was assumed that 100% of the target population would participate in the screening program. The impact of the participation rate on the cost-effectiveness of mammography screening was evaluated ranging from a 100% participation rate to a 23.6% participation rate which was derived from the national breast cancer screening program in Korea [22]. The costs and outcomes of mammography screening were compared with: (1) no screening (base case); (2) a combination of 5% private screening and 95% no screening; (3) a combination of 10% private screening and 90% no screening. A decision analytical modeling approach was used to detect patients with breast cancer (Fig 1). Women with an abnormal mammogram were taken for an extra laboratory test to diagnose breast cancer and were determined by the stage of cancer: stage I, stage II, stage III, stage IV or metastatic stage. We assumed that all breast cancer patients underwent prompt and adequate treatment. Women with a determined stage of cancer entered a Markov model linked to the decision tree model (Fig 2).

![Fig 1. Decision tree model.](https://doi.org/10.1371/journal.pone.0194996.g001)
Markov chain analysis was used to calculate costs and life years gained due to early detection of breast cancer. Entering the Markov model depends on the stage patients are being diagnosed. The five states in the Markov model are: remission (after treatment), local recurrence, distant recurrence, death due to breast cancer, and death due to other causes. In each one-year cycle, women can enter the remission state and remain there or make a transition to local recurrence, distant recurrence, death due to breast cancer, or death due to other causes. Women in the local recurrence state can remain in this state or make a transition to distant recurrence, death due to breast cancer or death due to other causes. Finally, women in the distant recurrence (including stage IV) can remain at the same state or make a transition to death due to breast cancer or death due to other causes [23]. The Markov model was run with a lifelong time horizon.

Model input parameters

Epidemiological parameters. Key parameters are summarized in Table 1. All-cause mortality probabilities by age were obtained from data published by the General Statistics Office of
Vietnam [24]. We used age-specific breast cancer incidence figures from online data of the International Agency for Research on Cancer [8]. Breast cancer stage distributions in the non-screened group were derived from a Vietnamese published article [25] while stage distributions in the screened group were obtained from the Chinese article of Wong et al. [17] as these parameter estimates were not available in Vietnam. Ductal carcinoma in situ (DCIS) was excluded from the model since epidemiological parameters related to DCIS were not recorded in Vietnam. Due to the lack of data, it was assumed that stage distributions in the screened group and the non-screened group were the same for each age group. We applied transition probabilities between health states in the Markov model from a Canadian study [23]. It was also assumed that transition probabilities between health states for the 60–64 age group were the same as that for the 50–59 age group. The survival probability of patients with stage IV breast cancer was estimated from a Vietnamese study [26] and was used to recalculate transition probabilities between health states in the Markov chain for scenario analyses (S1 Table).

**Sensitivity and specificity of mammography screening.** Due to the lack of data about the accuracy of mammography screening in Vietnamese women, the sensitivity and specificity of mammography screening programs were derived from a Japanese study [27].

**Costs.** The study was conducted from the viewpoint of the healthcare payer. Direct non-medical costs and indirect costs (like productivity losses) were not included in this study. The costs of tests were derived from a list of the Vietnamese Ministry of Health [28] and converted to the US dollar (US$ 1 = VND 22,330). In Vietnam, there are main laboratory tests to diagnose breast cancer, including tumor biopsy, cytological tests, ultrasound, and CA15.3 [26]. In this model, we assumed that among women with an abnormal mammogram, 50% required biopsy and 50% required cytological testing. Treatment costs were obtained from a previously published article of Nguyen Hoang Lan et al. [26]. These costs were adjusted to the year 2016 based on the Vietnamese Consumer Price Index [29] and included the initial treatment costs and follow-up costs. It was assumed that treatment costs were the same for each age group and the follow-up costs were the same for each cycle in the Markov model.

**Outcomes**

The model outcomes were: life year gained and total costs. The comparative performance of the strategies was measured by using an Increment Cost Effectiveness Ratio (ICER) and/or an Incremental Net Monetary Benefit (INMB). The ICER is defined as the difference in the total costs between the new screening program and the no screening alternative, divided by the difference in the effectiveness between these two options. The Net Monetary Benefit measures both cost and health outcome in terms of monetary value. Therefore, the INMB is calculated as the difference in effectiveness between both alternatives multiplied by a given willingness-to-pay threshold for a unit of effect gained, and then the difference in cost between both alternatives is subtracted from it [30]. The mammography screening is considered cost-effective if the ICER was less than 3 times the GDP per capita according to the WHO recommendation [31]. Both future health effects and costs were discounted at an annual rate of 3%. All analyses were conducted using the TreeAge Pro 2016 software.

**Uncertainty analyses**

To check the robustness of our results, we conducted one-way sensitivity analyses presented through a Tornado diagram. The parameters included in the one-way sensitivity analyses were as follows: discount rate, initial treatment cost, follow-up cost, mammography sensitivity, mammography specificity, and transition probabilities for the health states. Based on the literature, we determined a range of plausible values for the parameters in the model. In cases in
Table 1. Complete model input.

| Parameter | Value | Distribution | Reference |
|-----------|-------|--------------|-----------|
| **Epidemiology** | | | |
| **All-cause mortality: age distribution** | | Invariant | Vietnam [24] |
| 45–49 | 0.0037 | | |
| 50–54 | 0.0058 | | |
| 55–59 | 0.0094 | | |
| 60–64 | 0.0159 | | |
| 65–69 | 0.0271 | | |
| 70–74 | 0.0452 | | |
| 75–79 | 0.0680 | | |
| 80+ | 0.1129 | | |
| **Breast cancer incidence: age group** | | Beta<sup>a</sup> | Vietnam [8] |
| 45–49 | 0.000689 | | |
| 50–54 | 0.000829 | | |
| 55–59 | 0.000818 | | |
| 60–64 | 0.000685 | | |
| **Breast cancer stage distribution: screened** | | Dirichlet<sup>b</sup> | China [17] |
| Stage I | 0.521 | | |
| Stage II | 0.382 | | |
| Stage III | 0.057 | | |
| Stage IV | 0.041 | | |
| **Breast cancer stage distribution: non-screened** | | Dirichlet<sup>b</sup> | Vietnam [25] |
| Stage I | 0.1118 | | |
| Stage II | 0.6118 | | |
| Stage III | 0.1941 | | |
| Stage IV | 0.0823 | | |
| **Stage progression transition probabilities** | | Invariant | Canada [23] |
| **Age group 45–49** | | | |
| Stage I | Remission to Local recurrence | 0.01 | | |
| | Remission to Distant recurrence | 0.000016 | | |
| | Local recurrence to Distant recurrence | 0.062 | | |
| | Local recurrence to breast cancer death | 0.013 | | |
| | Distant recurrence to breast cancer death | 0.555 | | |
| Stage II&III | Remission to Local recurrence | 0.018 | | |
| | Remission to Distant recurrence | 0.024 | | |
| | Local recurrence to Distant recurrence | 0.165 | | |
| | Distant recurrence to breast cancer death | 0.386 | | |
| Stage IV | Distant recurrence to breast cancer death | 0.386 | | |
| **Age group 50–59** | | | |
| Stage I | Remission to Local recurrence | 0.009 | | |
| | Remission to Distant recurrence | 0.000025 | | |
| | Local recurrence to Distant recurrence | 0.052 | | |
| | Distant recurrence to breast cancer death | 0.137 | | |
| Stage II&III | Remission to Local recurrence | 0.016 | | |
| | Remission to Distant recurrence | 0.105 | | |
| | Local recurrence to Distant recurrence | 0.13 | | |
| | Distant recurrence to breast cancer death | 0.423 | | |
| Stage IV | Distant recurrence to breast cancer death | 0.423 | | |
| **Survival probability of patients in stage IV** | 0.50 | Invariant | Vietnam [26] |

(Continued)
which ranges could not be found from the previously published documents, the range of values that was used ±25% of the base-case as a conservative estimate (Table 2).

A probabilistic sensitivity analysis was performed to examine parameter uncertainty using second order Monte Carlo simulation with 10,000 iterations. In conducting a probabilistic sensitivity analysis, the distribution of each parameter was defined based on literature (Table 1).

### Table 2. Parameters and value ranges used for one-way sensitivity analysis.

| Parameter                                      | Low value          | High value          |
|------------------------------------------------|--------------------|---------------------|
| Mammography sensitivity                        | 75% of base-case value | 125% of base-case value |
| Mammography specificity                        | 75% of base-case value | 125% of base-case value |
| Transition rate from distant recurrence to cancer death | 50% of base-case value | 150% of base-case value |
| Transition rate from local recurrence to distant recurrence | 50% of base-case value | 150% of base-case value |
| Initial treatment cost                          | 75% of base-case value | 125% of base-case value |
| Follow-up cost                                  | 75% of base-case value | 125% of base-case value |
| Discount rate                                   | 0%                  | 6%                  |

https://doi.org/10.1371/journal.pone.0194996.t002

---

**Table 1. (Continued)**

| Parameter | Value | Distribution | Reference |
|-----------|-------|--------------|-----------|
| Mammography test |       |              |           |
| Sensitivity: age group |       |              |           |
| 45–49 | 0.714 | Beta<sup>c</sup> | Japan [27] |
| 50–59 | 0.858 |              |           |
| 60–64 | 0.872 |              |           |
| Specificity: age group |       |              |           |
| 45–49 | 0.886 | Beta<sup>c</sup> |           |
| 50–59 | 0.907 |              |           |
| 60–64 | 0.931 |              |           |
| Cost (US$) |       |              |           |
| Mammography test | 8.15 | Invariant | Vietnam [28] |
| Meeting with doctor | 1.75 | Invariant |           |
| Cost of further testing | Invariant |              |           |
| Biopsy | 6.45 |              | Vietnam [26] |
| Cytological test | 4.66 |              |           |
| Treatment costs |       |              |           |
| Initial treatment cost |       | Gamma<sup>d</sup> |           |
| Stage I | 160.00 |              |           |
| Stage II | 458.48 |              |           |
| Stage III | 850.45 |              |           |
| Stage IV | 668.70 |              |           |
| Follow-up cost | 88.57 | Gamma<sup>d</sup> |           |

<sup>a</sup> Parameters of the Beta distribution were derived from the number of cancer cases relative to the population by age groups.

<sup>b</sup> Parameter means of the distribution were equivalent to the sample size in each stage. Dirichlet was [1241;911;135;97] in the screened group and Dirichlet was [106;580;18478] in the non-screened groups.

<sup>c</sup> Parameters of the Beta distribution were derived from the number of cases having a positive result, a negative result, cancer, and no cancer.

<sup>d</sup> Costs were adjusted by the Vietnamese Consumer Price Index to the year 2016.

<sup>e</sup> The standard deviations for the initial treatment costs of stage I, II III and IV were US$190.76, US$546.64, US$1013.98, US$960.05, respectively. The standard deviation for costs of follow-up care was US$66.47.

https://doi.org/10.1371/journal.pone.0194996.t001
This analysis used the cost-effectiveness ceiling threshold (the willingness-to-pay threshold for a life year gained) of three times GDP per capita. The Vietnamese GDP per capita in 2015 was US$2,110.90 and the ceiling threshold, therefore, was US$6,332.70 per life year gained [32].

Ethics consideration
The Ethics Committee approval was not required for this cost-effectiveness study as model parameters in this study were obtained from previously published data.

Results
Table 3 shows the estimated average total costs and average total life years gained per 100,000 women under different screening strategies. Among the screening policies that were assessed, the first round of mammography screening in the 50–54 age group had the lowest ICER (US $3,647.06 per life year gained) and highest INMB (US$775,674). Mammography screening for women aged 55–59 years was estimated to gain 289 life years per 100,000 women and resulted in an ICER of US$4,405.44 when compared to no screening. According to the INMB decision rule (INMB > 0), screening for the 45–49 age group and the 60–64 age group could not be considered cost-effective since INMBs were negative.

Furthermore, the impact of opportunistic screening and the participation rate on the cost-effectiveness of mammography screening were explored since the rate of uptake in private screening and the participation rate in mammography were not available in Vietnam. The results showed that changing the percentage of individual screening from 0% to 10% had a minor effect on the cost-effectiveness of mammography screening (Table 4). In fact, the INMB turned out to be insensitive for changes in all screening policies: 100% no screening, 95% no screening + 5% individual screening and 90% no screening + 10% individual screening. However, changing the participation rate from 100% to 23.6% had a high impact on the INMBs of all age groups and mammography screening in the 50–54 age group, as well as the 55–59 age group, was considered cost-effective with an INMB of US$183,059 and US$108,337, respectively.

Due to the lack of Vietnamese data concerning transition probabilities between health states in the Markov model, parameters from a Canadian study were used. The average total cost, average total life years gained, the ICER and the INMB were analyzed by substitution of the survival rate of stage IV in Vietnam for that of the parameters in Canada and recalculation of

| Strategy          | Cost (US$) | Life year gained | ICER (US$) per patient | INMB (US$) |
|-------------------|------------|------------------|------------------------|------------|
| Women aged 45–49 years |            |                  |                        |            |
| No screening      | 115,603    | 100,520          |                        |            |
| Mammography screening | 1,169,942 | 100,640          | 8,782.70               | -294,117   |
| Women aged 50–54 years |          |                  |                        |            |
| No screening      | 104,134    | 100,096          |                        |            |
| Mammography screening | 1,157,487 | 100,385          | 3,647.06               | 775,674    |
| Women aged 55–59 years |          |                  |                        |            |
| No screening      | 99,351     | 99,689           |                        |            |
| Mammography screening | 1,148,683 | 99,928           | 4,405.44               |        459,055 |
| Women aged 60–64 years |          |                  |                        |            |
| No screening      | 79,603     | 98,897           |                        |            |
| Mammography screening | 1,110,692 | 99,060           | 6,335.84               |       -512  |

https://doi.org/10.1371/journal.pone.0194996.t003
transition probability parameters (Table 5). All ICERs of screening policies were lower than their counterparts in the base case. However, screening for the 45–49 age group was not considered to be cost-effective regarding the threshold of US$6332.70 since the ICER in this group was US$7,680.08. With these adjusted transition probability parameters, the ICER of mammography screening for women aged 60–64 reduced from US$6,335.84 to US$5,799.90 and was considered cost-effective.

### Sensitivity analyses

To test the impact of certain parameters on the ICERs, one-way sensitivity analyses were conducted for four screening policies. The eight parameters had an impact on the ICERs presented in Fig 3. The ICERs were most sensitive to the 'discount rate' in the four screening policies. ‘Mammography sensitivity’ had the second-highest impact on the ICERs in the three age groups: 45–49, 50–54, and 55–59 while ‘transition probability from remission to distant recurrence in stage II’ ranked the second among the parameters having a high effect on the ICER in the 60–64 age group.

We performed a probabilistic sensitivity analysis to test the robustness of the model. Fig 4 shows cost-effectiveness acceptability curves of four strategies based on different ceiling thresholds (Fig 4). Both screening for the 50–54 age group and the 55–59 age group would be cost-effective compared to no screening at the ceiling threshold of US$6,332.70 per life year gained. Compared to no screening for women aged 60–64, screening had a lower probability

### Table 5. Costs and effects of screening policies when using adjusted transition probability parameters.

| Strategy                | Cost (US$) | Life year gained | ICER (US$) | INMB (US$) |
|------------------------|------------|------------------|------------|-----------|
| **Women aged 45–49 years** |
| No screening           | 107,665    | 100,430          |            |           |
| Mammography screening  | 1,163,548  | 100,568          | 7,680.08   | -185,243  |
| **Women aged 50–54 years** |
| No screening           | 98,241     | 100,030          |            |           |
| Mammography screening  | 1,153,423  | 100,339          | 3,409.65   | 904,592   |
| **Women aged 55–59 years** |
| No screening           | 94,066     | 99,630           |            |           |
| Mammography screening  | 1,145,132  | 99,887           | 4,077.55   | 581,306   |
| **Women aged 60–64 years** |
| No screening           | 75,724     | 98,853           |            |           |
| Mammography screening  | 1,108,165  | 99,031           | 5,799.90   | 94,843    |
Fig 3. Impact of the parameters on the ICERs. D_R means discount rate; Dist_to_death_II: transition probability from distant recurrence to death in stage II; Dist_to_death_IV: transition probability from distant recurrence to death in stage IV; Local_to_dist_II: transition probability from local recurrence to distant recurrence in stage IV; R_to_dist_II: transition probability from remission to distant recurrence in stage II; R_to_local_I: transition probability from remission to local recurrence in stage I; R_to_local_II: transition probability from remission to local recurrence in stage II; Sensitivity: sensitivity of mammography; Specificity: specificity of mammography.

https://doi.org/10.1371/journal.pone.0194996.g003
of being cost-effective at the ceiling threshold since the screening program turned out to be cost-effective in only 46.32% of cases. Fig 4 illustrates that 0% of cases were cost-effective at the threshold if women aged 45–49 were screened.

**Discussion**

Low-cost screening approaches, such as clinical breast examination, could be implemented in limited resource settings as the WHO recommends. Presently, there are some studies regarding clinical breast examination as a method of breast cancer screening in Vietnam [33, 34]. However, these publications were cross-sectional studies with a small number of subjects and did not provide the necessary information on parameters such as sensitivity, specificity of clinical breast examination, and stage-specific diagnosis. So far, the only breast cancer screening
method that has been proven to be effective by early detection is mammography screening [2]. Accordingly, we analyzed the cost-effectiveness of mammography screening as compared to no screening in Vietnamese women.

Although mammography screening for early detection of breast cancer has been adopted in many Western countries, there are no data related to the effectiveness of mammography screening in Vietnam. As a result, we used parameters of breast cancer which were available in Vietnam and used other parameters from other countries to analyze the cost-effectiveness of mammography screening in Vietnamese women. Our results demonstrated that a single screening in the 50–54 age group, as well as the 55–59 age group, was cost-effective at the given ceiling threshold of US$6,332.7, while screening for women aged 45–49 years and women aged 60–64 years were not considered cost-effective. The reasons for this were that the incidence rate of breast cancer in these groups is lower than that of the other groups [8] and the mammography sensitivity in women in their 40s is relatively lower than for the older age groups [27, 35]. In addition, results from randomized trials showed no significant effect on breast cancer mortality in women between 40–49 years of age that were offered screening [36].

We also performed the cost-effectiveness of mammography screening in the second round for four specific age groups and only screening in women aged 50–54 years was considered cost-effective with an ICER of US$5,090.83 per life year gained (See S2 Table). This implies that increasing the screening frequencies for women aged 45–64 years will increase life years gained, but with decreasing cost-effectiveness of screening. More studies reported that cost per life year gained was reduced as the screening interval increased [23, 37, 38]. Annual and biennial mammography screening for women aged 45–64 years is not cost-effective because the ceiling threshold is quite low in Vietnam. However, we estimated the cost-effectiveness of the second round based on a lot of assumptions due to the lack of data, including similar stage distribution and transition probabilities as for the first round. It is expected that less aggressive cancer is in the subsequent screening in clinical practice. Consequently, long follow-up studies with a sufficient number of subjects should be conducted to estimate effectiveness of mammography screening in Vietnamese women.

We also analyzed the impact of opportunistic screening and the participation rate on the cost-effectiveness of mammography screening because of data scarcity in Vietnam. Our findings showed that changing individual screening from 0% to 10% had a minor effect on the cost-effectiveness of mammography screening while reducing the participation rate to 23.6% had a high impact on the INMBs of all screening policies because of the large effect on total costs. This was also found in the Canadian study [23].

The results of this study demonstrated that the discount rate, mammography sensitivity, and the transition rate in health states had a substantial impact on the ICER in all four groups. An important limitation in our study is the lack of data on mammography sensitivity for age-specific groups of Vietnamese women and we, therefore, had to use data from a Japanese study [27]. Factors such as age, screening interval, breast density, experience of trained professionals, and medical equipment could affect the sensitivity of mammography screening which were assumed to be similar to the Japanese condition.

Another limitation is that we applied transition probabilities between health states from a Canadian study. However, we adjusted these transition probability parameters based on the survival probability of stage IV of Vietnamese breast cancer patients which was lower than that of Canada. The number of deaths from breast cancer as a percentage of incident cases in low-income countries in 2008 was twice as high as that in high-income countries [39, 40]. The reasons for these high mortality rates due to breast cancer are the lack of awareness of breast cancer patients, inadequate facilities for detection and diagnosis, and poor access to high-quality treatment options in low and middle-income countries [40]. Breast cancer patients diagnosed
at the late-stages of breast cancer had significantly higher initial treatment costs than that at early-stages, while their survival probability was lower [26]. We found that all screening policies were more cost-effective when using adjusted transition probability parameters. Therefore, early detection of breast cancer through the national screening program would probably result in substantial improvements for the survival rate of patients in low- and middle-income countries whilst the treatment of breast cancer is still limited.

As for Vietnam, there is no information available on the rate of tests used to diagnose after screening. Therefore, only costlier invasive tests were included in the model to not underestimate the total cost associated with screening for breast cancer. We acknowledge that more non-invasive tests like ultrasound can also be part of the post-screening diagnosis pathway. After breast cancer patients complete an initial treatment, they are often required to continue treatment with follow-up care treatment and a range of methods is used in follow-up care depending on characteristics of patients and disease status, such as breast cancer stage, local recurrence and/or distant recurrence [26]. Due to the lack of such data, we assumed that cost for follow-up care was the same for all stage-specific diagnosis and all age groups. However, our one-way sensitivity analyses showed that the ICERs of all groups were insensitive to follow-up cost as well as initial treatment cost. Wong et al. also found that treatment costs had a minor impact on the ICER of breast cancer screening in Chinese women [17].

It has been well-known that the false-positive result is one of the harms of mammography screening [41]. The risk of false-positive results is higher in young women [42]. It leads to additional testing, such as biopsy, and ultrasound test, and is related to greater anxiety about breast cancer or required psychological support [43]. Nevertheless, Maria et al. revealed that women who experienced the false-positive mammogram still considered the false-positive result as an acceptable risk [44]. This study was conducted from a healthcare perspective and consequently, did not include non-medical costs or indirect costs outside healthcare in our models. In addition to the harms of breast cancer screening, over-diagnosis which refers to a tumor detected on screening and leads to be over-treated, is still remaining concern. DCIS—a noninvasive form of breast cancer— is considered to be potential factor related to over-diagnosis. Due to the lack of information on DCIS in Vietnamese women and the fact that there is currently no method of confirmation about the probability as well as timing from DCIS to invasive cancer [45], we did not take DCIS into account in the models. As a consequence, the cost-effectiveness of mammography screening could be overestimated and considered carefully before the national mammography program is introduced. At the individual level, benefits and risks should be informed by health staffs and balanced information should be considered as part of the personal decision-making process.

Although this study has limitations, the findings still provide the first piece of evidence regarding the cost-effectiveness of mammography screening in Vietnamese women. Currently, national programs and medical services covered by health insurance are not based on health-economic assessment in Vietnam. However, the application of health-economic assessments to medical services is considered to be mandatory when choosing health services. The results, therefore, provide valuable information for decision-makers to choose cost-effective interventions for breast cancer while the Vietnamese healthcare budget is limited. However, before introducing national mammography screening, other factors should be taken into account to make the implementation in Vietnamese circumstances successful. The results revealed that the participation rate had a high impact on the effectiveness of national breast cancer screening. Hence, women’s values and preferences, such as the enhanced awareness of breast cancer, preferred setting, time, and cost of travelling to a screening unit, cultural promotion for screening, and changing beliefs of health service providers, should be part of the decision process to encourage the higher uptake rate [46, 47]. Other assumptions, such as 100% adequate
treatment in patients, should be considered when cost-effectiveness results were interpreted in Vietnam. To reduce the mortality rate in breast cancer patients, the adequate treatment, along with mammography screening, should be noticed.

Conclusions
Our analyses have illustrated that the first round of mammography screening for the 50–54 age group is the most cost-effective age-related screening scenario and furthermore, both screening for the 50–54 age group and the 55–59 age group are cost-effective with the Vietnamese ceiling threshold. For women aged 45–49 years, mammography screening is not cost-effective since the incidence rate of breast cancer and the sensitivity of mammography in women in this age group are lower than that of the other groups. The discount rate, mammography sensitivity, and transition probability from remission to distant recurrence in stage II have a large impact on the ICER in all four age groups. Further studies should be conducted to examine the effectiveness of mammography screening and provide epidemiological data on breast cancer in Vietnamese women.

Supporting information
S1 Table. Adjusted transition probabilities between health states in the Markov model. (DOCX)
S2 Table. Cost-effectiveness of second round of mammography screening. (DOCX)

Acknowledgments
We thank the Editor Board of the General Statistics Office of Vietnam for providing access to Vietnamese data. We also thank the Nuclear Medicine and Oncology Center of Bach Mai Hospital for offering useful suggestions for our study. We express appreciation to Rebecca Prescott, MA, for significant comments for the manuscript.

Author Contributions
Conceptualization: Chi Phuong Nguyen, Eddy M. M. Adang.
Formal analysis: Chi Phuong Nguyen, Eddy M. M. Adang.
Methodology: Chi Phuong Nguyen, Eddy M. M. Adang.
Resources: Chi Phuong Nguyen, Eddy M. M. Adang.
Software: Chi Phuong Nguyen, Eddy M. M. Adang.
Supervision: Eddy M. M. Adang.
Visualization: Chi Phuong Nguyen.
Writing – original draft: Chi Phuong Nguyen, Eddy M. M. Adang.
Writing – review & editing: Chi Phuong Nguyen, Eddy M. M. Adang.

References
1. International Agency for Research on Cancer. Breast Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2012 [29/03/2017]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp.
2. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast Cancer Screening—Viewpoint of the IARC Working Group. New England journal of medicine. 2015; 372(24):2353–8. https://doi.org/10.1056/NEJMsr1504363 PMID: 26039523

3. Sankaranaranayan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010; 11(2):165–73. https://doi.org/10.1016/S1470-2045(09)70335-3 PMID: 20005175.

4. International Agency for Research on Cancer. Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012 [10/05/2017]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

5. World Health Organization. Breast cancer: prevention and control [20/03/2017]. Available from: http://www.who.int/cancer/detection/breastcancer/en/index1.html.

6. Duc NB. Epidemiology and program of control and prevention for cancer: preliminary report of National Cancer Project period 2008–2010. Vietnamese J Oncol. 2010; 1:21–6.(Vietnamese)

7. Phuong Dung (Yun) Trieu CM-T, Brennan Patrick C., Female breast cancer in Vietnam: a comparison across Asian specific regions. Cancer Biol Med. 2015; 12:238–45. https://doi.org/10.7497/j.issn.2095-3941.2015.0034 PMID: 26487968

8. Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst. 2006; 98(11):774–82. https://doi.org/10.1093/jnci/djj210 PMID: 16757702

9. Okonkwo Quirine Lamberts, Draisma Gerrit, der Kinderen Arno, Brown Martin L., Koning HJd. Breast Cancer Screening Policies in Developing Countries: A cost-effectiveness Analysis for India. J Natl Cancer Inst. 2008; 100(18):1290–300. https://doi.org/10.1093/jnci/djn292 PMID: 18780864

10. Kang MH, Park EC, Choi KS, Suh M, Jun JK, E. The national cancer screening program for breast cancer in the republic of korea: is it cost-effective? Asian Pacific journal of cancer prevention: APJCP. 2013; 14(3):2059–65. PMID: 23679319

11. Wong Irene O. L, Kuntz Karren M., Cowling Benjamin J., Lam CL, GM. L. Cost-effectiveness of Mammography screening for Chinese women. Cancer. 2007; 110(4):885–95. https://doi.org/10.1002/cncr.22848 PMID: 17607668

12. Oeffinger KC, Fontham ET, Etzioni R, Herzog A, Michaelson JS, Shih YC, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. Jama. 2015; 314(15):1599–614. Epub 2015/10/27. https://doi.org/10.1001/jama.2015.12783 PMID: 26501536; PubMed Central PMCID: PMC4831582.

13. Eun Hye Lee, Keum Won Kim, Young Joong Kim, Shin DR, Park YM, Lim HS, et al. Performance of Screening Mammography: A Report of the Alliance for Breast Cancer Screening in Korea. Korean J Radiol. 2016; 17(4):489–96. https://doi.org/10.3348/kjr.2016.17.4.489 PMID: 27390540

14. Ministry of Health of Singapore. Cancer screening: MOH clinical practice guidelines. 2010.

15. Hamashima C, Japanese Research Group for the Development of Breast Cancer Screening Guidelines, Hamashima C C, Hattori M, Honjo S, Kasahara Y, et al. The Japanese Guidelines for Breast Cancer Screening. Japanese Journal of Clinical Oncology. 2016; 46(5):482–92. https://doi.org/10.1093/jjco/hyw008 PMID: 27207993
22. Kim Yeonju, Jun Jae Kwan, Choi Kui Son, Lee Hoo-Yeon, Park E-C. Overview of the National Cancer Screening Programme and the Cancer Screening Status in Korea. Asian Pacific J Cancer Prev. 2011; 12(3):725–30.
23. Gocgun Y BD, Taghipour S, Montgomery N, Harvey BJ, Jardine AK, Miller AB. Cost-effectiveness of breast cancer screening policies using simulation. The breast. 2015; 24(4):440–8. https://doi.org/10.1016/j.breast.2015.03.012 PMID: 25866350
24. General statistics office of Vietnam. Census of population and housing in Vietnam in 2009. 2011. (Vietnamese)
25. Hoang Lan N, Lachasirirong W SJ. Survival probability and prognostic factors for breast cancer patients in Vietnam. Global health action 2013; 6:1–9.
26. Hoang Lan N, Lachasirirong W, Stewart JF, Tung ND, Coyle PC. Cost of treatment for breast cancer in central Vietnam. Global health action. 2013; 6:18872. https://doi.org/10.3402/gha.v6i0.18872 PMID: 23394855
27. Suzuki A, Kuriyama S, Kawai M, Amari M, Takeda M, Ishida T, et al. Age-specific interval breast cancers in Japan: estimation of the proper sensitivity of screening using a population-based cancer registry. Cancer sci. 2008; 99(1):2264–7. https://doi.org/10.1111/j.1349-7006.2008.00926.x PMID: 18795941
28. Vietnamese Ministry of Health, Vietnamese Ministry of Finance. Circular No. 37/2015 / TTLT-BYT-BTC. 2015. (Vietnamese)
29. General statistics office of Vietnam. Consumer price index 2017 [19/03/2017]. Available from: http://www.gso.gov.vn/default_en.aspx?tabid = 625.
30. Michael F. Drummond MJ, Claxton Karl, Stoddart Greg L., Torrance George W. Methods for the Economic Evaluation of Health Care Programmes. 4th ed: Oxford University Press; 2015.
31. T. Tan-Torres Edejer, R. Baltussen, T. Adam, R. Hutubessy, A. Acharya, D.B. Evan, et al. Making choices in health: WHO guide to cost-effectiveness analysis Geneva: World Health Organization; 2003.
32. World bank. GDP per capita (current US$) 2016 [12/05/2017]. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
33. Thuan TV. Results of screening for early detection of breast and cervical cancer in Que Vo—Bac Ninh in 2009. Journal of Practical Medicine. 2011; 756(3):29–32. (Vietnamese)
34. Hung Nguyen Tuan, Thuan TV. The screening results for early detection of breast and cervical cancer in some cities or provinces from 2008 to 2010 Journal of Practical Medicine. 2012; 815(4):61–3. (Vietnamese)
35. Armstrong Katrina, Moye Elizabeth, Williams Sankey, Berlin Jesse A., Reynolds EE. Screening mammography in women 40–49 years of age: a systematic review for the American College of Physicians. Annals of internal medicine. 2007; 146(7):516–26. https://doi.org/10.7326/0003-4819-146-7-200704030-00008 PMID: 17404354
36. van den Ende C, Oordt-Speets AM, Vroling H, HME. vA. Benefits and harms of breast cancer screening with mammography in women aged 40–49 years: A systematic review. Int J Cancer. 2017. https://doi.org/10.1002/ijc.30794.
37. Shahpar Haghighat MEA, Yavari Parvin, Javanbakht Mehdi, Ghaffari Shahram. Cost-effectiveness of three rounds of mammography breast cancer screening in Iranian women. Iran J Cancer Prev. 2016; 9 (1). https://doi.org/10.17795/ijc-5443.
38. Woo PP, Kim JJ, GM L. What is the most cost-effective population-based cancer screening program for Chinese women? J Clin Oncol. 2007; 25(6):617–24. https://doi.org/10.1200/JCO.2006.06.0210 PMID: 17308266
39. World Health Organization: International Agency for Research on Cancer. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide in 2008. 2008. Available from: http://globocan.iarc.fr/.
40. Lawrence N. Shulman WW, Amy Sievers, Knaul Felicia M. Breast Cancer in Developing Countries: Opportunities for Improved Survival. Journal of Oncology. 2010. https://doi.org/10.1155/2010/595167.
41. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. Jama. 2014; 311(13):1327–35. Epub 2014/04/03. https://doi.org/10.1001/jama.2014.1398 PMID: 24691608.
42. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Annals of internal medicine. 2011; 155(8):481–92. Epub 2011/10/19. https://doi.org/10.7326/0003-4819-155-8-201110180-00004 PMID: 22007042; PubMed Central PMCID: PMC309800.
43. European Commission Initiative on Breast Cancer. Should organised mammography screening vs. no mammography screening be used for early detection of breast cancer in women aged 50 to 69? [20/02/2018]. Available from: http://ecibc.jrc.ec.europa.eu/recommendations/details/3.
44. Maria D. Thomson LAS. Perspectives on mammography after receipt of secondary screening owing to a false positive. Women's health issues: official publication of the Jacobs Institute of Women's Health. 2015; 25(2):128–33. Epub 2015/02/05. https://doi.org/10.1016/j.whi.2014.11.003 PMID: 25648490; PubMed Central PMCID: PMCPMC4355242.

45. Morris E, Feig SA, Drexler M, Lehman C. Implications of Overdiagnosis: Impact on Screening Mammography Practices. Population health management. 2015; 18 Suppl 1:S3–11. Epub 2015/09/29. https://doi.org/10.1089/pop.2015.29023mor PMID: 26414384; PubMed Central PMCID: PMCPMC4589101.

46. Azami-Aghdash S, Ghojazadeh M, Sheyklo SG, Daemi A, Kolahdouzan K, Mohseni M, et al. Breast Cancer Screening Barriers from the Woman's Perspective: a Meta-synthesis. Asian Pacific journal of cancer prevention: APJCP. 2015; 16(8):3463–71. Epub 2015/04/30. PMID: 25921163.

47. Linsell L, Forbes LJ, Patnick J, Wardle J, Austoker J, Ramirez AJ. Women's preferences for the delivery of the National Health Service Breast Screening Programme: a cross-sectional survey. Journal of medical screening. 2010; 17(4):176–80. Epub 2011/01/25. https://doi.org/10.1258/jms.2010.010037 PMID: 21258127.